BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab

Abstract : BCL2 mutations have been suggested to confer an adverse prognosis to follicular lymphoma (FL) patients, but their prognostic value has not been assessed in patients treated with a rituximab-containing regimen. Here we evaluated the prognostic value of BCL2 mutations in a large prospective cohort of 252 patients with FL treated with immunochemotherapy in the PRIMA randomized trial. Using a DNA-targeted sequencing approach, we detected amino acid altering mutations in 135 patients (54%) and showed that these mutations were probably mediated by the over-activation of AICDA (activation-induced cytidine deaminase) in the context of the t(14;18) translocation. The BCL2 variants identified in PRIMA patients affected the BH1, BH2, and BH3 functional motifs at a lower frequency than the N-terminus and flexible loop domain, with mostly conservative aminoacid changes. With a median follow-up of 6.7 years, we did not observe any impact of BCL2 mutations either on overall survival or progression-free survival.
Document type :
Journal articles
Complete list of metadatas

Cited literature [19 references]  Display  Hide  Download

https://hal.inria.fr/hal-01524901
Contributor : Marie-France Sagot <>
Submitted on : Monday, July 24, 2017 - 3:24:43 PM
Last modification on : Thursday, April 18, 2019 - 3:28:41 PM

File

huet2017_2.pdf
Files produced by the author(s)

Identifiers

Citation

Sarah Huet, Edith Szafer-Glusman, Bruno Tesson, Luc Xerri, Wayne J. Fairbrother, et al.. BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab. American Journal of Hematology, Wiley, 2017, 92 (6), pp.515 - 519. ⟨10.1002/ajh.24701⟩. ⟨hal-01524901⟩

Share

Metrics

Record views

287

Files downloads

539